Publicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (67)

2024

  1. Heteroatom-tagged proteomics of lung cancer and chronic obstructive pulmonary disease human serum reveal alterations in selenoproteins

    Microchemical Journal, Vol. 199

  2. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113

  3. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

2023

  1. Metallomic Signatures of Lung Cancer and Chronic Obstructive Pulmonary Disease

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

  2. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

    Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516

  3. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

    Genome Medicine, Vol. 15, Núm. 1

2022

  1. Decreased Long-Term Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019

    Liver Transplantation, Vol. 28, Núm. 6, pp. 1039-1050

  2. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

    Journal for immunotherapy of cancer, Vol. 10, Núm. 11

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort

    Respiratory research, Vol. 22, Núm. 1, pp. 36

  3. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients

    American Journal of Transplantation, Vol. 21, Núm. 8, pp. 2876-2884

  4. Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD

    Chest, Vol. 160, Núm. 3, pp. 872-878

  5. Corrigendum to “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules” [J Hepatol (2019) 874–884] (Journal of Hepatology (2019) 70(5) (874–884), (S0168827819300157), (10.1016/j.jhep.2019.01.005))

    Journal of Hepatology

  6. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  7. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients

    Journal of Hepatology, Vol. 74, Núm. 1, pp. 148-155

  8. Immunologic characterization of COVID-19 patients with hematological cancer

    Haematologica

  9. Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD: Importance of Sex

    Chest, Vol. 160, Núm. 2, pp. 481-490

  10. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

    European Journal of Radiology, Vol. 135

  11. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2019

  1. Effect of risk of malnutrition on 30-day mortality among older patients with acute heart failure in Emergency Departments

    European Journal of Internal Medicine, Vol. 65, pp. 69-77